Biotech Regulatory Trends

Peter Thiel discusses the regulatory challenges facing the biotech industry, questioning if the FDA will become less restrictive due to global market shifts. With insights on the impact of aging populations on drug approvals, the conversation delves into potential changes in regulatory environments for biotech advancements.